miRNA与哮喘气道炎症及内型的研究进展  

Research progress of miRNA in asthma:airway inflammation and endotype

作　　者：鲍八虎 刘维英[2] 叶育才 陈国荣 孙静梓 胡澳燕 BAO Bahu;LIU Weiying;YE Yucai;CHEN Guorong;SUN Jingzi;HU Aoyan(The First Clinical Medical College of Lanzhou University,Lanzhou 730030,Gansu,China;Department of Respiratory and Critical Care Medicine,Lanzhou University First Hospital,Lanzhou 730030,Gansu,China)

机构地区：[1]兰州大学第一临床医学院,甘肃兰州730030 [2]兰州大学第一医院呼吸与危重症医学科,甘肃兰州730030

出　　处：《中国临床药理学与治疗学》2024年第10期1194-1200,共7页Chinese Journal of Clinical Pharmacology and Therapeutics

基　　金：甘肃省自然科学基金(21JRIRA074)。

摘　　要：微小RNA(microRNA,miRNA)是一种长度约为22nt的单链非编码RNA,参与机体的多种生理及病理过程。支气管哮喘是一种异质性疾病,气道炎症是其发病的重要机制之一,根据发病过程中免疫机制的差异分为不同内型,不同内型哮喘气道炎症的作用机制也有所区别。本文就miRNA在哮喘气道炎症及内型中的研究进展进行综述,探究miRNA在哮喘气道炎症及内型中的发病机制和治疗前景。microRNA(miRNA)is a 22nt long single-stranded non-coding RNA that is involved in a variety of physiological and pathological processes.Bronchial asthma is a heterogeneous disease,and airway inflammation is one of the important mechanisms of its pathogenesis.Asthma can be classified into different types based on the different immune mechanisms involved in its pathogenesis,and the mechanism of airway inflammation also varies between different types of asthma.This article reviews the research progress of miRNA in asthma airway inflammation and endotype,and explores the pathogenesis and treatment prospects of miRNA in asthma airway inflammation and endotype.

关 键 词：支气管哮喘 气道炎症 MIRNA 内型 

分 类 号：R256.12[医药卫生—中医内科学]